HY004 / Juventas Cell Therapy - LARVOL DELTA

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Juventas Cell Therapy Ltd. | N=80 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • BCL2 • BCL6 • CD22

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Juventas Cell Therapy Ltd. | N=50 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov) - P1 | N=2 | Terminated | Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Active, not recruiting ➔ Terminated; Due to adjustments in the company's strategy, the research and development of this project has been terminated.

Trial termination • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD22

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: Juventas Cell Therapy Ltd. | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • IL6

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1/2 | N=80 | Not yet recruiting | Sponsor: Juventas Cell Therapy Ltd. | Trial completion date: Sep 2026 ➔ Jun 2027 | Trial primary completion date: Dec 2024 ➔ Jun 2026

Trial completion date • Trial primary completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • BCL2 • BCL6 • CD22 • IL6

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: Juventas Cell Therapy Ltd. | Initiation date: Oct 2023 ➔ Aug 2024

Trial initiation date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • IL6

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1/2 | N=80 | Not yet recruiting | Sponsor: Juventas Cell Therapy Ltd. | Initiation date: Oct 2023 ➔ Aug 2024

Trial initiation date • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CD22 • IL6

Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - P1/2 | N=80 | Not yet recruiting | Sponsor: Juventas Cell Therapy Ltd.

New P1/2 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • CD22

A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) (clinicaltrials.gov) - P1/2 | N=50 | Not yet recruiting | Sponsor: Juventas Cell Therapy Ltd.

New P1/2 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

Mucilaginibacter celer sp. nov. and Aquirhabdus parva gen. nov., sp. nov., isolated from freshwater. (PubMed, Int J Syst Evol Microbiol) - "nov. (type strain HYN0046=KACC 19178=NBRC 112739) in the family Moraxellaceae and phylum Proteobacteria."

Journal